Harnessing The Power of The Placenta
Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the postpartum placenta. We have multiple cell therapy candidates in pre-clinical and clinical development as well as placental-derived products for surgical use.
Bolster the immune system against cancer & infectious diseases
Modulate the immune system in inflammation-related and autoimmune diseases
Promote regeneration and repair in degenerative diseases
Deploy the unique biological materials derived from the placenta in products for functional regeneration
Developing a Potential Treatment for COVID-19
As the COVID-19 pandemic threatens lives across the globe, the team at Celularity realized that our anti-cancer candidate product, CYNK-001, also has the potential to be effective against infectious diseases such as COVID-19.
This product uses placental-derived natural killer (NK) cells, which can augment the normal immune response by killing virus-infected cells. Preclinical studies are now underway.
Celularity in the News
FDA Green-Lights Clinical Trial For COVID-19 Coronavirus Treatment That ‘Flattens The Curve’ In Patients
Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19
First cell treatment to fight the coronavirus awaits FDA approval for clinical trial
Cell Therapy Pipeline
We are investigating transformative allogeneic cellular therapies, engineered from the postpartum human placenta, for use in cancer immunotherapy, infectious disease, allergy and autoimmune disease treatment, and functional regeneration.
Scalable, In-House GMP Manufacturing
Our clinical and commercial products are manufactured in our state-of-the-art, 150,000 square-foot, GMP/ GTP facility.
Because our manufacturing process is highly modular, production is efficient, scalable, and reproducible.